Last reviewed · How we verify
E: Peg-interferon alpha-2a & Ribavirin
E: Peg-interferon alpha-2a & Ribavirin is a Antiviral combination therapy Small molecule drug developed by Kaohsiung Medical University Chung-Ho Memorial Hospital. It is currently FDA-approved for Chronic hepatitis C virus infection. Also known as: Pegasys, Robatrol.
Pegylated interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis and replication.
Peg-interferon alpha-2a and Ribavirin are used to treat Hepatitis C, as indicated by ClinicalTrials.gov. The mechanism of action of Peg-interferon alpha-2a and Ribavirin is not specified in the provided facts, but according to ChEMBL, Peg-interferon alpha-2a is an interferon that interferes with viral replication, and Ribavirin is a nucleoside analog that inhibits viral RNA synthesis.
At a glance
| Generic name | E: Peg-interferon alpha-2a & Ribavirin |
|---|---|
| Also known as | Pegasys, Robatrol |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Drug class | Antiviral combination therapy |
| Target | Interferon-alpha receptor; viral RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Peg-interferon alpha-2a is a long-acting form of interferon that binds to interferon-alpha receptors on immune cells, triggering antiviral and immunomodulatory effects including upregulation of MHC molecules and activation of natural killer cells. Ribavirin is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase and depletes cellular guanosine pools, reducing viral replication. Together, they provide synergistic antiviral activity.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Hemolytic anemia
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Headache
- Insomnia
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E: Peg-interferon alpha-2a & Ribavirin CI brief — competitive landscape report
- E: Peg-interferon alpha-2a & Ribavirin updates RSS · CI watch RSS
- Kaohsiung Medical University Chung-Ho Memorial Hospital portfolio CI
Frequently asked questions about E: Peg-interferon alpha-2a & Ribavirin
What is E: Peg-interferon alpha-2a & Ribavirin?
How does E: Peg-interferon alpha-2a & Ribavirin work?
What is E: Peg-interferon alpha-2a & Ribavirin used for?
Who makes E: Peg-interferon alpha-2a & Ribavirin?
Is E: Peg-interferon alpha-2a & Ribavirin also known as anything else?
What drug class is E: Peg-interferon alpha-2a & Ribavirin in?
What development phase is E: Peg-interferon alpha-2a & Ribavirin in?
What are the side effects of E: Peg-interferon alpha-2a & Ribavirin?
What does E: Peg-interferon alpha-2a & Ribavirin target?
Related
- Drug class: All Antiviral combination therapy drugs
- Target: All drugs targeting Interferon-alpha receptor; viral RNA-dependent RNA polymerase
- Manufacturer: Kaohsiung Medical University Chung-Ho Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Virology/Infectious Disease
- Indication: Drugs for Chronic hepatitis C virus infection
- Also known as: Pegasys, Robatrol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing